Stoke Therapeutics (NASDAQ:STOK) Announces Earnings Results

Stoke Therapeutics (NASDAQ:STOK) announced its earnings results on Thursday. The company reported ($0.79) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.01, FiscalAI reports. The business had revenue of $6.23 million for the quarter, compared to analysts’ expectations of $6.48 million. Stoke Therapeutics had a negative return on equity of 2.05% and a negative net margin of 3.73%.

Here are the key takeaways from Stoke Therapeutics’ conference call:

• Four?year OLE results show durable seizure reductions (median ~59–91% in reported intervals) and statistically significant improvements across five Vineland?3 subdomains over years 1–4, with zorevunersen described as generally well?tolerated despite common CSF protein elevations that lacked serious clinical manifestations.
• Phase III EMPEROR enrollment has been rapid — ~130 patients randomized to date, ~91 have received the two 70 mg loading doses, 18 completed the week?28 primary endpoint visit, and the company expects to finish randomizing ~150 patients in the U.S./U.K./Japan by June with a mid?2027 readout and a rolling NDA start in Q1 2027.
• Commercial and labeling plans emphasize using the long?term OLE data (section 14/supplementary studies) to support prescriber guidance and payer discussions, a focused payer engagement program (national account directors) and a lean commercial model targeting an estimated ~6,000 addressable U.S. patients aged ?25 at launch.
• Financial runway — Stoke reported ~$411 million in cash and marketable securities at quarter end and raised ~$80.7 million via an ATM program, which it says funds operations through a potential U.S. launch in late 2027/early 2028.

Stoke Therapeutics Stock Up 0.3%

NASDAQ:STOK traded up $0.10 on Friday, reaching $32.89. 693,127 shares of the company’s stock traded hands, compared to its average volume of 725,005. The stock has a 50-day simple moving average of $34.34 and a 200-day simple moving average of $32.03. Stoke Therapeutics has a 12 month low of $8.70 and a 12 month high of $40.22. The firm has a market cap of $2.05 billion, a PE ratio of -274.06 and a beta of 1.20.

Insider Activity

In other Stoke Therapeutics news, CFO Thomas Leggett sold 2,382 shares of the company’s stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $31.34, for a total value of $74,651.88. Following the completion of the transaction, the chief financial officer directly owned 10,172 shares in the company, valued at $318,790.48. This represents a 18.97% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, General Counsel Jonathan Allan sold 4,628 shares of the stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $31.34, for a total transaction of $145,041.52. Following the sale, the general counsel directly owned 28,836 shares of the company’s stock, valued at approximately $903,720.24. This trade represents a 13.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 69,699 shares of company stock valued at $2,526,714 in the last three months. 9.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Stoke Therapeutics

Several institutional investors have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Stoke Therapeutics by 5.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company’s stock worth $162,000 after purchasing an additional 1,149 shares in the last quarter. Goldman Sachs Group Inc. grew its position in shares of Stoke Therapeutics by 21.4% during the first quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company’s stock valued at $11,053,000 after purchasing an additional 293,072 shares in the last quarter. Jane Street Group LLC increased its holdings in shares of Stoke Therapeutics by 125.2% in the first quarter. Jane Street Group LLC now owns 26,978 shares of the company’s stock worth $179,000 after purchasing an additional 15,001 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Stoke Therapeutics by 26.6% in the second quarter. JPMorgan Chase & Co. now owns 25,655 shares of the company’s stock worth $291,000 after buying an additional 5,398 shares in the last quarter. Finally, Rhumbline Advisers boosted its stake in Stoke Therapeutics by 33.9% during the second quarter. Rhumbline Advisers now owns 66,419 shares of the company’s stock valued at $754,000 after buying an additional 16,820 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on STOK shares. Chardan Capital reiterated a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, March 18th. Wolfe Research began coverage on shares of Stoke Therapeutics in a research report on Monday, February 23rd. They set an “outperform” rating and a $40.00 target price for the company. Canaccord Genuity Group upped their target price on shares of Stoke Therapeutics from $36.00 to $60.00 and gave the company a “buy” rating in a report on Friday, March 20th. Wedbush increased their price target on shares of Stoke Therapeutics from $36.00 to $38.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 17th. Finally, Wall Street Zen cut shares of Stoke Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $41.83.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.